

Freedom of Information Request: Our Reference CTHB_10_19

You asked:

Within your Organisation, how many Intra-vitreous Injections / Implants have been used in the latest 4 months, if possible between September and December 2018. If your Organisation is able to identify Injections / Implants by eye conditions please split by the drug used (Ranibizumab, Bevacizumab, Aflibercept, Fluocinolone and Dexamethasone).

Our response:

In response to your recent request, the table you have provided has been populated with the number of injections administered during the period of 1st September and 31st December '18, by medicine and by diagnosed eye condition.

Please see the table as follows:

	Lucentis (Ranibizumab) Injections	Avastin (Bevacizumab) Injections	Eylea (Aflibercept) Injections	Iluvien (Fluocinolone) Implants	Ozurdex (Dexamethasone) Implants
TOTAL	615	10	572		
Wet Age Related Macular Degeneration (wAMD)	338		354		
Diabetic Macular Oedema (DMO)	165		123		**
Retinal Vein Occlusion – Central or Branch (CRVO or BRVO)	98		95		**
Other eg mCNV	14	10	**		

Where it has been indicated ** patient numbers are less than 5, therefore figures have been withheld due to the low numbers involved

Where numbers are low, we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain.

Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.